Actively Recruiting
Comparative Efficacy of Antibiotics for Small Intestine Bacterial Overgrowth in Bangladeshi Children
Led by University of Virginia · Updated on 2026-05-06
60
Participants Needed
1
Research Sites
19 weeks
Total Duration
On this page
Sponsors
U
University of Virginia
Lead Sponsor
N
National Institutes of Health (NIH)
Collaborating Sponsor
AI-Summary
What this Trial Is About
The purpose of this Phase IIa study is to identify the most effective antibiotic regimen to treat small intestine bacterial overgrowth (SIBO) in impoverished Bangladeshi children.
CONDITIONS
Official Title
Comparative Efficacy of Antibiotics for Small Intestine Bacterial Overgrowth in Bangladeshi Children
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Positive glucose hydrogen breath test (GHBT)
- Weight-for-age Z score greater than -1
- Length-for-age Z score greater than -1
You will not qualify if you...
- Known chronic or congenital illness, including developmental delay
- Acute gastrointestinal illness within the past 14 days
- Antibiotic use within the past 14 days
- Previous adverse reaction to any of the study antibiotics or related drugs
- Sibling previously enrolled in this study
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b)
Dhaka, Bangladesh
Actively Recruiting
Research Team
J
Jeffrey R Donowitz, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here